NeuroOne Medical Technologies has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Evo sEEG Electrode technology.

Evo sEEG Electrode technology is NeuroOne’s second FDA 510(k) cleared product.

The clearance will enable the company to market the Evo sEEG Electrodes for temporary use with recording, monitoring and stimulation equipment. It can be used for recording, monitoring and stimulation of electrical signals at the subsurface level of the brain.

However, unlike cortical electrodes, sEEG electrodes use a much less invasive process and do not require removal of the top portion of the patient’s skull.

Commenting on the 510(k) clearance, NeuroOne CEO Dave Rosa said: “This represents yet another critical milestone met by the company as we continue to execute our strategy.

“The next steps for the company are to expand the sEEG labelling for longer-term use, which we believe will be a key part of our commercialisation strategy for the Evo sEEG electrode, and complete development of an sEEG ablation electrode/probe for ablation of brain tissue and permanently implanted stimulation electrodes for patients with chronic applications such as epilepsy, Parkinson’s disease and chronic back pain.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s portfolio of hi-definition thin film electrodes also includes the Evo Cortical, which received FDA clearance in November 2019.

According to NeuroOne, the potential advantages of the devices are increased signal clarity, better tactile feedback during insertion into brain tissue and faster deliveries due to an automated manufacturing process.